Effect of cyproheptadine administration on insulin secretion in acromegalic, diabetic and normal subjects

J. M. Feldman, C. H. Bivens, Jay S Skyler, H. E. Lebovitz

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The effect of cyproheptadine (Cypro) and Placebo administration on insulin secretion and glucose utilization following i.v. glucose (IVGTT) was evaluated in 8 normal, 7 diabetic and 8 acromegalic subjects. Five of the diabetic subjects had overt diabetes and 2 of the diabetic subjects had 'chemical' diabetes (oral GTT). One of the acromegalic subjects had overt diabetes, while one had borderline glucose tolerance and 6 had normal glucose tolerance (oral GTT). Cypro increased insulin secretion in the acromegalic but not in the diabetic or normal subjects. Methysergide (Methy) increased insulin secretion in acromegalic and diabetic subjects but not in normal subjects. Methy and Cypro both increased insulin secretion in the same acromegalic subjects. None of the 3 groups of subjects had a modification in insulin secretion following Placebo administration. Neither Placebo, Cypro or Methy altered the glucose utilization rate constant (KG). There was no change in insulin half life or tissue sensitivity to insulin from Cypro (normal and acromegalic subjects) or Methy (normal subjects) administration. Despite their increase in insulin secretion in response to serotonin antagonists, acromegalic subjects have normal urinary 5 hydroxyindoleacetic acid excretion and normal serum serotonin concentrations. Their response cannot therefore be attributed to a generalized overproduction of serotonin.

Original languageEnglish
Pages (from-to)279-283
Number of pages5
JournalHormone and Metabolic Research
Volume7
Issue number4
StatePublished - Dec 1 1975
Externally publishedYes

Fingerprint

Cyproheptadine
Methysergide
Insulin
Glucose
Medical problems
Serotonin
Placebos
Placebo Effect
Serotonin Antagonists
Hydroxyindoleacetic Acid
Glucose Tolerance Test
Type 2 Diabetes Mellitus
Half-Life
Insulin Resistance
Rate constants
Tissue
Serum

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Effect of cyproheptadine administration on insulin secretion in acromegalic, diabetic and normal subjects. / Feldman, J. M.; Bivens, C. H.; Skyler, Jay S; Lebovitz, H. E.

In: Hormone and Metabolic Research, Vol. 7, No. 4, 01.12.1975, p. 279-283.

Research output: Contribution to journalArticle

@article{14ba4c65a519470882121df0183bae22,
title = "Effect of cyproheptadine administration on insulin secretion in acromegalic, diabetic and normal subjects",
abstract = "The effect of cyproheptadine (Cypro) and Placebo administration on insulin secretion and glucose utilization following i.v. glucose (IVGTT) was evaluated in 8 normal, 7 diabetic and 8 acromegalic subjects. Five of the diabetic subjects had overt diabetes and 2 of the diabetic subjects had 'chemical' diabetes (oral GTT). One of the acromegalic subjects had overt diabetes, while one had borderline glucose tolerance and 6 had normal glucose tolerance (oral GTT). Cypro increased insulin secretion in the acromegalic but not in the diabetic or normal subjects. Methysergide (Methy) increased insulin secretion in acromegalic and diabetic subjects but not in normal subjects. Methy and Cypro both increased insulin secretion in the same acromegalic subjects. None of the 3 groups of subjects had a modification in insulin secretion following Placebo administration. Neither Placebo, Cypro or Methy altered the glucose utilization rate constant (KG). There was no change in insulin half life or tissue sensitivity to insulin from Cypro (normal and acromegalic subjects) or Methy (normal subjects) administration. Despite their increase in insulin secretion in response to serotonin antagonists, acromegalic subjects have normal urinary 5 hydroxyindoleacetic acid excretion and normal serum serotonin concentrations. Their response cannot therefore be attributed to a generalized overproduction of serotonin.",
author = "Feldman, {J. M.} and Bivens, {C. H.} and Skyler, {Jay S} and Lebovitz, {H. E.}",
year = "1975",
month = "12",
day = "1",
language = "English",
volume = "7",
pages = "279--283",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "4",

}

TY - JOUR

T1 - Effect of cyproheptadine administration on insulin secretion in acromegalic, diabetic and normal subjects

AU - Feldman, J. M.

AU - Bivens, C. H.

AU - Skyler, Jay S

AU - Lebovitz, H. E.

PY - 1975/12/1

Y1 - 1975/12/1

N2 - The effect of cyproheptadine (Cypro) and Placebo administration on insulin secretion and glucose utilization following i.v. glucose (IVGTT) was evaluated in 8 normal, 7 diabetic and 8 acromegalic subjects. Five of the diabetic subjects had overt diabetes and 2 of the diabetic subjects had 'chemical' diabetes (oral GTT). One of the acromegalic subjects had overt diabetes, while one had borderline glucose tolerance and 6 had normal glucose tolerance (oral GTT). Cypro increased insulin secretion in the acromegalic but not in the diabetic or normal subjects. Methysergide (Methy) increased insulin secretion in acromegalic and diabetic subjects but not in normal subjects. Methy and Cypro both increased insulin secretion in the same acromegalic subjects. None of the 3 groups of subjects had a modification in insulin secretion following Placebo administration. Neither Placebo, Cypro or Methy altered the glucose utilization rate constant (KG). There was no change in insulin half life or tissue sensitivity to insulin from Cypro (normal and acromegalic subjects) or Methy (normal subjects) administration. Despite their increase in insulin secretion in response to serotonin antagonists, acromegalic subjects have normal urinary 5 hydroxyindoleacetic acid excretion and normal serum serotonin concentrations. Their response cannot therefore be attributed to a generalized overproduction of serotonin.

AB - The effect of cyproheptadine (Cypro) and Placebo administration on insulin secretion and glucose utilization following i.v. glucose (IVGTT) was evaluated in 8 normal, 7 diabetic and 8 acromegalic subjects. Five of the diabetic subjects had overt diabetes and 2 of the diabetic subjects had 'chemical' diabetes (oral GTT). One of the acromegalic subjects had overt diabetes, while one had borderline glucose tolerance and 6 had normal glucose tolerance (oral GTT). Cypro increased insulin secretion in the acromegalic but not in the diabetic or normal subjects. Methysergide (Methy) increased insulin secretion in acromegalic and diabetic subjects but not in normal subjects. Methy and Cypro both increased insulin secretion in the same acromegalic subjects. None of the 3 groups of subjects had a modification in insulin secretion following Placebo administration. Neither Placebo, Cypro or Methy altered the glucose utilization rate constant (KG). There was no change in insulin half life or tissue sensitivity to insulin from Cypro (normal and acromegalic subjects) or Methy (normal subjects) administration. Despite their increase in insulin secretion in response to serotonin antagonists, acromegalic subjects have normal urinary 5 hydroxyindoleacetic acid excretion and normal serum serotonin concentrations. Their response cannot therefore be attributed to a generalized overproduction of serotonin.

UR - http://www.scopus.com/inward/record.url?scp=0016838223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016838223&partnerID=8YFLogxK

M3 - Article

C2 - 1150128

AN - SCOPUS:0016838223

VL - 7

SP - 279

EP - 283

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 4

ER -